A Study to Assess CT-868 and the Relationship Between Insulin Secretory Response and Ambient Blood Glucose

Carmot Therapeutics, Inc.32 enrolled

Overview

A Study to Assess the Effect of CT-868 and the Relationship Between Insulin Secretory Response and Ambient Blood Glucose in Obese Male Subjects and Subjects with T2DM.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

Conditions

Diabetes

Interventions

CT-868 as SC InjectionDRUG

CT-868

Placebo as SC InjectionDRUG

Placebo

Active Comparator as SC InjectionDRUG

Active Comparator

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Part 1: Obese Otherwise Healthy Males * Part 2: Males or Females with T2D * Part 1: BMI 30.0-35.0, inclusive * Part 2: BMI 27.0-45.0, inclusive * 18-65 years old, inclusive * Stable body weight for 2 months Exclusion Criteria: * Significant medical history * Uncontrolled hypertension * History of malignancy

Locations (1)

Carmot Clinical Research Unit 101

Chula Vista, California, United States

Outcomes

Primary Outcomes

Change in insulin secretion rate and ambient glucose levels

Time frame: Baseline up to 4 days

Secondary Outcomes

Change in blood insulin levels at each level of glucose infusion

Time frame: Baseline up to 4 days

Change in blood glucose levels at each level of glucose infusion

Time frame: Baseline up to 4 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.